Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome — Piero Ruggenenti (2000) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome
Shared by
Giuseppe Remuzzi
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome
Article
2000
en
Authors
+4 more
PR
Piero Ruggenenti
LM
Lidia Mosconi
GV
Giovanni Vendramin
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2010
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
Paolo Cravedi
,
Varusca Brusegan
,
Piero Ruggenenti
,
Ruth Campbell
,
Giuseppe Remuzzi
Article
2004
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome
Arrigo Schieppati
,
Annalisa Perna
,
Javier Zamora
,
Giovanni Giuliano
,
Norbert Braun
,
Giuseppe Remuzzi
Article
1991
Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy
Andrea Remuzzi
,
Elena Perticucci
,
Piero Ruggenenti
,
Lidia Mosconi
,
Margherita Limonta
,
Giuseppe Remuzzi
Article
1999
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
Andrea Remuzzi
,
Norberto Perico
,
Fabio Sangalli
,
Giovanni Vendramin
,
M. Moriggi
,
Piero Ruggenenti
,
Giuseppe Remuzzi
Article
1991
Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome.
Giuseppe D’Amico
,
Giuseppe Remuzzi
,
G Maschio
,
M. G. Gentile
,
Eliana Gotti
,
Lamberto Oldrizzi
,
G. M. Manna
,
G Mecca
,
Carlo Rugiu
,
G. Fellin
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.